Fluoxymesterone is a 17-alpha-alkylated oral anabolic-androgenic steroid. Halogenation at position 9 increases the pharmacologic activity per unit weight compared to testosterone when given orally and reduces aromatization. It is a strong androgen with limited anabolic activity. Fluoxymesterone can be reduced by 5-alpha reductase into DHT and some of it’s androgenic activity may be caused not by fluoxymesterone itself, but to its metabolite DHT.
Fluoxymesterone used in hypogonadal males to induce normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. Effects also include growth and maturation of prostate, seminal vesicles, penis, and scrotum; development of male hair distribution, such as beard, pubic, chest, and axillary hair; laryngeal enlargement; vocal cord thickening; alterations in body musculature; and fat distribution. Therefore, main indications for fluoxymesterolone are: primary hypogonadism (congenital or acquired) – testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy; hypogonadotropic hypogonadism (congenital or acquired) – idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.
Metastatic mammary cancer – may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries.
|each tablet contains:|
Packing: 100 tablets in a Glass Vial
Dosage and administration
The daily adult dosage is 10-20 mg.
Cholestatic hepatitis and jaundice occur with 17-alpha-alkylated androgens at a relatively low dose. If cholestatic hepatitis with jaundice appears or if liver function tests become abnormal, the androgen should be discontinued and the etiology should be determined. Drug-induced jaundice is reversible when the medication is discontinued.
Contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate and in women who are or may become pregnant. When administered to pregnant women, androgens cause virilization of the external genitalia of the female fetus. This virilization includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure.